新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 百时美施贵宝 » 施贵宝放弃其抗抑郁症药物BMS-820836研究

施贵宝放弃其抗抑郁症药物BMS-820836研究

来源:生物谷 2013-08-14 20:57

2013年8月14日讯 /生物谷BIOON/ --Albany Molecular Research公司周一透露,其合作伙伴,制药巨头施贵宝公司放弃了抗抑郁症药物BMS-820836的研究,原因是研究人员在中期实验中,BMS-820836相比于礼来公司的同类产品并不具有优势,未能达到预期目标。礼来公司的抗抑郁症药物Cymbalta将于今年晚些时候失去专利保护效力,施贵宝公司原本希望借此时机通过该药物扩大市场份额。

对于各大药企,抑郁症药物一直是一个研究难点,阿斯利康公司、葛兰素史克公司等制药巨头都曾在这个领域折戟。(生物谷Bioon.com)

详细英文报道:

Shares of Albany Molecular Research ($AMRI) took a hit Monday afternoon after it reported that its development partner Bristol-Myers Squibb ($BMY) decided to scuttle an experimental depression therapy that failed to compare favorably with a blockbuster Eli Lilly ($LLY) treatment in midstage trials.

In a document filed with the SEC, AMRI said that BMS-820836--an investigational triple reuptake inhibitor in a pair of midstage studies for treatment-resistant depression--failed the primary endpoints when compared to Eli Lilly's Cymbalta (duloxetine), which loses patent protection later this year.

AMRI Chief Executive Thomas D'Ambra told Reuters that the program was the most advanced therapy in a package of four drugs identified by BMS under a development pact struck back in 2005. BMS had paid out $15.5 million in milestones for the program.

"We expect to have further discussions at some future date to decide about their plans for this compound or any other compound," D'Ambra added. AMRI shares dropped 10% on the news Monday afternoon.

Depression has been a tough target for big drug developers. AstraZeneca ($AZN) experienced some bitter setbacks in the field, which have been so prevalent that GlaxoSmithKline ($GSK) R&D chief Moncef Slaoui decided to drop its work several years ago. Drug developers say it's hard to anticipate how well an experimental depression drug will do against an established rival or even a placebo.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库